Chimeric virus-like particles made using GAG and M1 capsid proteins providing dual drug delivery and vaccination platform.

Nanobiomaterials such as enveloped virus-like particles with specificity can serve a dual function of vaccination and drug delivery system. Here, we expressed colon carcinoma cell-targeting chimeric virus-like particles (VLPs) made using two capsid proteins, gag and M1 from influenza virus A/swine flu/Iowa/15/30/H1N1 in silkworms. These chimeric VLPs displayed a glycosylphosphatidylinositol-anchored single-chain variable fragment region targeting colon carcinoma cells, and their shape was smooth, with an average particle size of 21 nm in diameter. Large unilamellar vesicles made from DOPC:DOPA (2:1) containing calcein-AM (10 μM) or doxorubicin (13.7 nM) were used to package chimeric VLPs. VLPs showed high specificity in targeting cancer cells and delivered the dye and drug to cells successfully. Chimeric VLPs were injected into BALB/c mice, and the serum showed specificity for M1 protein as a model.

[1]  Daniel Agudelo,et al.  Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: structural features and biological implications. , 2014, International journal of biological macromolecules.

[2]  E. Park,et al.  A Model for Targeting Colon Carcinoma Cells Using Single-Chain Variable Fragments Anchored on Virus-Like Particles via Glycosyl Phosphatidylinositol Anchor , 2014, Pharmaceutical Research.

[3]  M. Zheng,et al.  Development of universal influenza vaccines based on influenza virus M and NP genes , 2014, Infection.

[4]  Ashish Ranjan,et al.  Tumor Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam Radiotherapy and Thermally Sensitive Nanocarriers , 2013, Theranostics.

[5]  Chung-Hyun Cho,et al.  Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function. , 2013, Free radical biology & medicine.

[6]  E. Park,et al.  Display of Neospora caninum surface protein related sequence 2 on Rous sarcoma virus-derived gag protein virus-like particles. , 2013, Journal of biotechnology.

[7]  Jijin Gu,et al.  Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. , 2013, Biomaterials.

[8]  H. Pasolli,et al.  Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice , 2012, The open virology journal.

[9]  R. Compans,et al.  Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. , 2012, Virology.

[10]  Min-Chul Kim,et al.  Virus-like particles as universal influenza vaccines , 2012, Expert review of vaccines.

[11]  E. Park,et al.  Expression of an RSV-gag virus-like particle in insect cell lines and silkworm larvae. , 2011, Journal of virological methods.

[12]  E. Park,et al.  Production of Rous sarcoma virus-like particles displaying human transmembrane protein in silkworm larvae and its application to ligand-receptor binding assay. , 2011, Journal of biotechnology.

[13]  L. Parent.  New insights into the nuclear localization of retroviral gag proteins , 2011, Nucleus.

[14]  K. Tsumoto,et al.  Confocal microscopic observation of fusion between baculovirus budded virus envelopes and single giant unilamellar vesicles. , 2010, Biochimica et biophysica acta.

[15]  Holger Sudhoff,et al.  Molecular targeted therapies in head and neck cancer - An update of recent developements - , 2010, Head & neck oncology.

[16]  D. Francis,et al.  The Lack of an Inherent Membrane Targeting Signal Is Responsible for the Failure of the Matrix (M1) Protein of Influenza A Virus To Bud into Virus-Like Particles , 2010, Journal of Virology.

[17]  Andrew K. Udit,et al.  Metal- and metallocycle-binding sites engineered into polyvalent virus-like scaffolds. , 2010, Bioconjugate chemistry.

[18]  J. Fiedler,et al.  Assembly of hybrid bacteriophage Qbeta virus-like particles. , 2009, Biochemistry.

[19]  P. Roy,et al.  Virus‑like particles as a vaccine delivery system: Myths and facts , 2008, Human vaccines.

[20]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[21]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[22]  S. Palmer,et al.  Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. , 2006, Health Technology Assessment.

[23]  Martin Fischlechner,et al.  Virus-engineered colloidal particles--a surface display system. , 2006, Angewandte Chemie.

[24]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[25]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[26]  M. Nishikawa.  Development of cell-specific targeting systems for drugs and genes. , 2005, Biological & pharmaceutical bulletin.

[27]  D. Peer,et al.  Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. , 2004, Neoplasia.

[28]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[29]  P. Roy,et al.  Virus-like particles as immunogens. , 2003, Trends in microbiology.

[30]  John E. Johnson,et al.  Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. , 2003, Biomacromolecules.

[31]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[32]  J. Galarza,et al.  Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins , 2001, Journal of Virology.

[33]  V. Vogt,et al.  Characterization of Rous Sarcoma Virus Gag Particles Assembled In Vitro , 2001, Journal of Virology.

[34]  V. Vogt,et al.  Mass Determination of Rous Sarcoma Virus Virions by Scanning Transmission Electron Microscopy , 1999, Journal of Virology.

[35]  M. Luo,et al.  Structural similarities between influenza virus matrix protein M1 and human immunodeficiency virus matrix and capsid proteins: an evolutionary link between negative-stranded RNA viruses and retroviruses. , 1999, The Journal of general virology.

[36]  C. Cameron,et al.  An assembly domain of the Rous sarcoma virus Gag protein required late in budding , 1994, Journal of virology.